Immunotherapy does not impair ovarian function in a mouse model of breast cancer - Takeaways - MDSpire

Immunotherapy does not impair ovarian function in a mouse model of breast cancer

  • By

  • Payton De La Cruz

  • Morgan F. Woodman-Sousa

  • Julia N. McAdams

  • Ellia Sweeney

  • Lola Hakim

  • Melanie Morales Aquino

  • Kathryn J. Grive

  • July 2, 2026

  • 0 min

Share

  • 1

    Triple negative breast cancer (TNBC) accounts for 15%-20% of breast cancer cases and is more common in reproductive-age women.

  • 2

    Chemotherapy for TNBC often leads to infertility and endocrine disruption, affecting many women undergoing treatment.

  • 3

    Immunotherapies targeting PD-1, LAG-3, and TIM-3 showed no negative impact on ovarian function or hormone levels in a TNBC mouse model.

  • 4

    The study suggests that immunotherapy may be a viable option for fertility-sparing treatment in women with TNBC.

  • 5

    Standard-of-care PD-1 inhibitors do not adversely affect ovarian architecture or hormone homeostasis in treated mice.

Original Source(s)

Immunotherapy does not impair ovarian function in a mouse model of breast cancer

  • by Payton De La Cruz, Morgan F. Woodman-Sousa, Julia N. McAdams, Ellia Sweeney, Lola Hakim, Melanie Morales Aquino, Kathryn J. Grive

  • July 2, 2026

Related Content

A novel bimanual endoluminal robotic platform compatible with standard gastroscopes for endoscopic submucosal dissection: preclinical feasibility and ergonomic evaluation

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

  • July 2, 2026

  • 1 min
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min